Table 4.
Approach to sedation and alternative pulmonary vasodilator strategies for HRF, in patients with concomitant HIE undergoing TH, according to center type.
| TnECHO centers (n = 12) | Non-TnECHO centers (n = 59) | P value | |
|---|---|---|---|
| Sedation/analgesia strategies | |||
| Routine narcotic infusion | 10 (83) | 32 (54) | 0.05 |
| Routine benzodiazepine administration | 0 | 2 (3) | NS |
| Intermittent or continuous muscle relaxation | 3 (25) | 24 (41) | NS |
| Dexmedetomidine infusion | 0 | 6 (10) | NS |
| Pulmonary vasodilator therapies | |||
| Inhaled nitric oxide first line | 12 (100) | 49 (85) | NS |
| Milrinone | 6 (50) | 50 (85) | 0.01 |
| Sildenafil | 4 (33) | 16 (27) | NS |
| Prostacyclin analog | 2 (17) | 11 (19) | NS |
| Bosentan | 0 | 1 (2) | NS |
NS not significant.